Journal article icon

Journal article

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma.

Abstract:
Twenty-one patients with recurrent or progressive glioblastoma were enrolled in a prospective phase II trial to determine the safety and efficacy of a 1-week on/1-week off regimen of temozolomide administered at 150 mg/m2 on days 1 to 7 and days 15 to 21 of 28-day treatment cycles. Two patients achieved a partial response (10%), and 17 patients (81%) had stable disease. The median progression-free survival was 5 months. The progression-free survival at 6 months was 48%.

Actions


Access Document


Authors


Steinbach, JP More by this author
Küker, WM More by this author
Dichgans, J More by this author
Bamberg, M More by this author
Expand authors...
Journal:
Neurology
Volume:
62
Issue:
11
Pages:
2113-2115
Publication date:
2004-06-05
DOI:
EISSN:
1526-632X
ISSN:
0028-3878
URN:
uuid:ee5c7ff6-1053-4b38-be28-5911518a2248
Source identifiers:
242880
Local pid:
pubs:242880

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP